|

casdatifan Clinical Trials

5 actively recruiting trials across 5 locations

▲ +2 trials since August 2026

Also known as: AB521, C21H17F4NO3S

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Arcus Biosciences, Inc.2
  • Pfizer1
  • Dana-Farber Cancer Institute1
  • Bristol-Myers Squibb1

Indications

  • Cancer5
  • Clear Cell Renal Cell Carcinoma2
  • Advanced Renal Cell Carcinoma (RCC)1
  • Metastatic/Advanced Renal Cell Carcinoma1
  • Metastatic Renal Cell Cancer1

Birmingham, Alabama1 trial

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Research Site

Phase 1

Gilbert, Arizona1 trial

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Research Site

Phase 3

Phoenix, Arizona1 trial

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Mayo Clinic Building- Phoenix

Phase 1/2

Palo Alto, California1 trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Local Institution - 0178

Phase 1/2

Boston, Massachusetts1 trial

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

Beth Israel Deaconess Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.